Organon & Co. Share Price Today: Live Updates & Key Insights

Organon & Co. share price today is $6.03, up -3.83%. The stock opened at $6.29 against the previous close of $6.27, with an intraday high of $6.3 and low of $6.02.

Organon & Co. Share Price Chart

Organon & Co.

us-stock
To Invest in {{usstockname}}
us-stock

Organon & Co. Share Price Performance

$6.03 -0.0383(-3.83%) OGN at 23 Mar 2026 02:35 PM Drug Manufacturers - General
Lowest Today 6.02
Highest Today 6.3
Today’s Open 6.29
Prev. Close 6.27
52 Week High 15.70
52 Week Low 6.02
Day’s Range: Low 6.02 High 6.3
52-Week Range: Low 6.02 High 15.70
1 day return -
1 Week return -4.81
1 month return -23.7
3 month return -13.66
6 month return -42.87
1 year return -60.64
3 year return -72.39
5 year return -81.14
10 year return -

Organon & Co. Institutional Holdings

Vanguard Group Inc 14.18

BlackRock Inc 11.85

iShares Core S&P Small-Cap ETF 6.07

State Street Corp 3.59

AQR Capital Management LLC 3.29

Vanguard Total Stock Mkt Idx Inv 3.16

LSV Asset Management 2.87

Massachusetts Financial Services Company 2.64

Vanguard Small Cap Index 2.26

Vanguard Equity-Income Inv 1.94

Geode Capital Management, LLC 1.77

Morgan Stanley - Brokerage Accounts 1.67

Private Management Group Inc 1.67

Vanguard Small Cap Value Index Inv 1.45

MFS Mid Cap Value A 1.42

MFS Mid Cap Value Equity 1.42

Kahn Brothers & CO Inc /DE/ 1.39

Bank of New York Mellon Corp 1.37

D. E. Shaw & Co LP 1.30

Dimensional Fund Advisors, Inc. 1.30

Charles Schwab Investment Management Inc 1.12

First Trust Health Care AlphaDEX® ETF 1.08

Vanguard Institutional Extnd Mkt Idx Tr 1.08

UBS Group AG 1.06

Gotham Asset Management, LLC 1.02

iShares S&P Small-Cap 600 Value ETF 0.97

Canada Pension Plan Investment Board 0.93

State Street SPDR Port S&P 600 Sm CpETF 0.93

Two Sigma Investments LLC 0.83

Vanguard Strategic Equity Inv 0.81

Citadel Advisors Llc 0.79

Jane Street Group LLC 0.77

State St Russell Sm/Mid Cp® Indx SL Cl I 0.57

State Street® SPDR® S&P 600™ Sm CpValETF 0.56

AQR Long-Short Equity I 0.54

Fidelity Extended Market Index 0.52

Schwab US Small-Cap ETF™ 0.48

Vanguard High Dividend Yield ETF 0.40

Principal SmallCap S&P 600 Idx SP 0.39

Invesco S&P SmallCap 600 Revenue ETF 0.38

Organon & Co. Market Status

Strong Buy: 0

Buy: 2

Hold: 3

Sell: 2

Strong Sell: 0

Organon & Co. Fundamentals

Market Cap 1569.70 M

PB Ratio 2.0874

PE Ratio 8.375

Enterprise Value 9639.70 M

Total Assets 12867.00 M

Volume 6336029

Organon & Co. Company Financials

Annual Revenue FY25:6216000000 6216.0M, FY23:6150000000 6150.0M, FY22:6174000000 6174.0M, FY21:6304000000 6304.0M, FY20:8096000000 8096.0M

Annual Profit FY25:3362000000 3362.0M, FY23:3724000000 3724.0M, FY22:3880000000 3880.0M, FY21:3922000000 3922.0M, FY20:4749000000 4749.0M

Annual Net worth FY25:187000000 187.0M, FY23:585000000 585.0M, FY22:917000000 917.0M, FY21:1351000000 1351.0M, FY20:2160000000 2160.0M

Quarterly Revenue Q4/2025:1507000000 1507.0M, Q3/2025:1602000000 1602.0M, Q2/2025:1594000000 1594.0M, Q1/2025:1513000000 1513.0M, Q3/2024:1582000000 1582.0M

Quarterly Profit Q4/2025:759000000 759.0M, Q3/2025:857000000 857.0M, Q2/2025:874000000 874.0M, Q1/2025:841000000 841.0M, Q3/2024:923000000 923.0M

Quarterly Net worth Q4/2025:-205000000 -205.0M, Q3/2025:160000000 160.0M, Q2/2025:145000000 145.0M, Q1/2025:87000000 87.0M, Q3/2024:359000000 359.0M

About Organon & Co. & investment objective

Company Information Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1

Organisation Drug Manufacturers - General

Employees 10000

Industry Drug Manufacturers - General

CEO Mr. Joseph T. Morrissey Jr.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Organon & Co. FAQs

What is the share price of Organon & Co. today?

The current share price of Organon & Co. is $6.03.

Can I buy Organon & Co. shares in India?

Yes, Indian investors can buy Organon & Co. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Organon & Co. shares in India?

You can easily invest in Organon & Co. shares from India by:

Can I buy fractional shares of Organon & Co.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Organon & Co.?

Organon & Co. has a market cap of $1569.70 M.

In which sector does Organon & Co. belong?

Organon & Co. operates in the Drug Manufacturers - General sector.

What documents are required to invest in Organon & Co. stocks?

To invest, you typically need:

What is the PE and PB ratio of Organon & Co.?

The PE ratio of Organon & Co. is 8.38 and the PB ratio is 2.09.